Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
November 05, 2024
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-WorldJune 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentOctober 16, 2024
Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical OperationsOctober 3, 2024
Kite Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for the Evaluation of Yescarta® (axicabtagene ciloleucel) CAR T-cell Therapy as First-Line Treatment for Patients with High-Risk Large B-Cell Lymphoma